Sara Sheikhbahaei

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1373049/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Imaging of Cancer Immunotherapy: Response Assessment Methods, Atypical Response Patterns, and Immune-Related Adverse Events, From the <i>AJR</i> Special Series on Imaging of Inflammation. American Journal of Roentgenology, 2022, 218, 940-952.	2.2	5
2	Malignant Paraganglioma with Brown Adipose Tissue Activation. Radiographics, 2022, 42, E14-E15.	3.3	1
3	Exposing the Hidden Curriculum in Radiology Training: A True 360° Evaluation. Radiographics, 2022, 42, E9-E11.	3.3	0
4	¹⁷⁷ Luâ€₽SMA radioligand therapy effectiveness in metastatic castrationâ€resistant prostate cancer: An updated systematic review and metaâ€analysis. Prostate, 2022, 82, 826-835.	2.3	20
5	Diagnostic performance of IQ·SPECT with high-speed scanning: A preliminary quality control study in obese patients. Journal of Nuclear Cardiology, 2022, 29, 3443-3449.	2.1	1
6	2-Deoxy-2-[18F] Fluoro-d-Glucose PET/Computed Tomography. PET Clinics, 2022, 17, 307-317.	3.0	0
7	Burden of Neurological Disorders Across the US From 1990-2017. JAMA Neurology, 2021, 78, 165.	9.0	262
8	CTâ€based assessment of body composition following neoadjuvant chemohormonal therapy in patients with castrationâ€naÃ⁻ve oligometastatic prostate cancer. Prostate, 2021, 81, 127-134.	2.3	9
9	Cellular and Molecular Imaging with SPECT and PET in Brain Tumors. Radiologic Clinics of North America, 2021, 59, 363-375.	1.8	5
10	Applications of artificial intelligence in oncologic 18F-FDG PET/CT imaging: a systematic review. Annals of Translational Medicine, 2021, 9, 823-823.	1.7	32
11	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177–labeled Prostate-specific Membrane Antigen–targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. European Urology, 2021, 80, 82-94.	1.9	53
12	Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. American Journal of Roentgenology, 2021, 217, 495-506.	2.2	6
13	Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Respiratory Medicine,the, 2021, 9, 1030-1049.	10.7	86
14	PET Imaging for Head and Neck Cancers. Radiologic Clinics of North America, 2021, 59, 773-788.	1.8	13
15	Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CT. Clinical Lung Cancer, 2020, 21, 485-497.	2.6	10
16	The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 582-597.	8.1	241
17	The global, regional, and national burden of colorectal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 913-933.	8.1	259
18	The global, regional, and national burden of pancreatic cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2019, 4, 934-947.	8.1	372

SARA SHEIKHBAHAEI

#	Article	IF	CITATIONS
19	Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls. Seminars in Nuclear Medicine, 2019, 49, 255-270.	4.6	81
20	18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies. Annals of Nuclear Medicine, 2019, 33, 351-361.	2.2	50
21	Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 376-393.	10.2	359
22	Impact of aging on semiquantitative uptake parameters in normal rated clinical baseline [1231]Ioflupane single photon emission computed tomography/computed tomography. Nuclear Medicine Communications, 2019, 40, 1001-1004.	1.1	5
23	EnsurePlus as an Alternative to the Standardized Egg Gastric-Emptying Meal. Clinical Nuclear Medicine, 2019, 44, 459-461.	1.3	11
24	Imaging of Nonprostate Cancers Using PSMA-Targeted Radiotracers: Rationale, Current State of the Field, and a Call to Arms. Journal of Nuclear Medicine, 2018, 59, 871-877.	5.0	115
25	Use of quantitative SPECT/CT reconstruction in 99mTc-sestamibi imaging of patients with renal masses. Annals of Nuclear Medicine, 2018, 32, 87-93.	2.2	17
26	Nuclear Scintigraphy in Practice: Gastrointestinal Motility. American Journal of Roentgenology, 2018, 211, 260-266.	2.2	18
27	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. Annals of Nuclear Medicine, 2018, 32, 512-522.	2.2	37
28	Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. Clinical Nuclear Medicine, 2017, 42, e227-e234.	1.3	34
29	Post-treatment 18F-FDC-PET/CT versus contrast-enhanced CT in patients with oropharyngeal squamous cell carcinoma. Nuclear Medicine Communications, 2017, 38, 250-258.	1.1	4
30	Defining the Added Value of 99mTc-MIBI SPECT/CT to Conventional Cross-Sectional Imaging in the Characterization of Enhancing Solid Renal Masses. Clinical Nuclear Medicine, 2017, 42, e188-e193.	1.3	28
31	18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas. Clinical Nuclear Medicine, 2017, 42, e16-e21.	1.3	19
32	Health Effects of Overweight and Obesity in 195 Countries over 25 Years. New England Journal of Medicine, 2017, 377, 13-27.	27.0	5,014
33	Whole-Body ¹⁸ F-FDG PET and ¹⁸ F-FDG PET/CT in Patients with Suspected Paraneoplastic Syndrome: A Systematic Review and Meta-Analysis of Diagnostic Accuracy. Journal of Nuclear Medicine, 2017, 58, 1031-1036.	5.0	31
34	Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2117-2136.	6.4	234
35	Comparative effectiveness. Nuclear Medicine Communications, 2017, 38, 720-725.	1.1	5
36	Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up ¹⁸ F-FDG PET/CT Scans in Oncology Patients. Journal of Nuclear Medicine, 2017, 58, 737-743.	5.0	10

SARA SHEIKHBAHAEI

#	Article	IF	CITATIONS
37	Molecular Imaging and Precision Medicine. PET Clinics, 2017, 12, 105-118.	3.0	16
38	The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer. American Journal of Roentgenology, 2017, 208, 420-433.	2.2	91
39	Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted 18F-DCFPyL in peripheral ganglia. Annals of Nuclear Medicine, 2017, 31, 696-702.	2.2	34
40	Prevalence and Years Lived with Disability of 310 Diseases and Injuries in Iran and its Neighboring Countries, 1990-2015: Findings from Global Burden of Disease Study 2015. Archives of Iranian Medicine, 2017, 20, 392-402.	0.6	9
41	Disability-Adjusted Life-Years (DALYs) for 315 Diseases and Injuries and Healthy Life Expectancy (HALE) in Iran and its Neighboring Countries, 1990-2015: Findings from Global Burden of Disease Study 2015. Archives of Iranian Medicine, 2017, 20, 403-418.	0.6	18
42	18F-FDG-PET/CT therapy assessment of locally advanced pancreatic adenocarcinoma. Nuclear Medicine Communications, 2016, 37, 231-238.	1.1	28
43	Value of fourth and subsequent post-therapy follow-up 18F-FDG PET/CT scans in patients with breast cancer. Nuclear Medicine Communications, 2016, 37, 602-608.	1.1	2
44	The Role of Positron Emission Tomography/Computed Tomography in Management and Prediction of Survival in Pancreatic Cancer. Journal of Computer Assisted Tomography, 2016, 40, 142-151.	0.9	7
45	FDG Avidity and Tumor Burden: Survival Outcomes for Patients With Recurrent Breast Cancer. American Journal of Roentgenology, 2016, 206, 846-855.	2.2	15
46	FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies. Oncologist, 2016, 21, 931-939.	3.7	174
47	Impact of point spread function reconstruction on quantitative 18F-FDG-PET/CT imaging parameters and inter-reader reproducibility in solid tumors. Nuclear Medicine Communications, 2016, 37, 288-296.	1.1	12
48	18F-FDG PET/CT and Melanoma. Clinical Nuclear Medicine, 2016, 41, e403-e409.	1.3	18
49	Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features. American Journal of Roentgenology, 2016, 207, 641-647.	2.2	27
50	FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. American Journal of Roentgenology, 2016, 206, 1093-1100.	2.2	16
51	¹⁸ F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. Journal of Nuclear Medicine, 2016, 57, 855-860.	5.0	40
52	Contribution of vitamin D deficiency to the risk of coronary heart disease in subjects with essential hypertension. Atherosclerosis, 2016, 244, 165-171.	0.8	21
53	Use of ¹⁸ F-Fludeoxyglucose–Positron Emission Tomography/Computed Tomography for Patient Management and Outcome in Oropharyngeal Squamous Cell Carcinoma. JAMA Otolaryngology - Head and Neck Surgery, 2016, 142, 79.	2.2	27
54	Non-linear contribution of serum vitamin D to symptomatic diabetic neuropathy: A case-control study. Diabetes Research and Clinical Practice, 2016, 111, 44-50.	2.8	18

SARA SHEIKHBAHAEI

#	Article	IF	CITATIONS
55	The Global Burden of Cancer 2013. JAMA Oncology, 2015, 1, 505.	7.1	2,269
56	PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer. PET Clinics, 2015, 10, 197-205.	3.0	9
57	18F FDG PET/CT and Head and Neck Cancer. PET Clinics, 2015, 10, 125-145.	3.0	24
58	Authors' reply. Journal of Cardiology, 2015, 65, 440.	1.9	0
59	An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects. Neurological Sciences, 2015, 36, 1121-1126.	1.9	44
60	Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas. PET Clinics, 2015, 10, 375-393.	3.0	28
61	Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. American Journal of Roentgenology, 2015, 205, 1102-1113.	2.2	22
62	Assessment of serum 25-hydroxy vitamin D improves coronary heart disease risk stratification in patients with type 2 diabetes. American Heart Journal, 2015, 170, 573-579.e5.	2.7	35
63	Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 2015, 205, 629-639.	2.2	80
64	Is the evaluation of Entamoeba histolytica infection in HIV-positive patients of any clinical significance?. Acta Medica Iranica, 2015, 53, 46-50.	0.8	5
65	Comparing the Predictive Ability of Prognostic Models in Ischemic Stroke; Derivation, Validation, and Discrimination Beyond the ROC Curve. Frontiers in Neurology, 2014, 5, 9.	2.4	1
66	Serum thyroid stimulating hormone, total and free T4 during the neonatal period: Establishing regional reference intervals. Indian Journal of Endocrinology and Metabolism, 2014, 18, 39.	0.4	21
67	Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 957-979.	13.7	609
68	Serum Uric Acid, the Metabolic Syndrome, and the Risk of Chronic Kidney Disease in Patients with Type 2 Diabetes. Metabolic Syndrome and Related Disorders, 2014, 12, 102-109.	1.3	22
69	Trends in the prevalence of diabetes and impaired fasting glucose in association with obesity in Iran: 2005–2011. Diabetes Research and Clinical Practice, 2014, 103, 319-327.	2.8	197
70	Homocysteine and metabolic syndrome: From clustering to additional utility in prediction of coronary heart disease. Journal of Cardiology, 2014, 64, 290-296.	1.9	33
71	Risk of coronary heart disease associated with metabolic syndrome and its individual components in Iranian subjects: A matched cohort study. Journal of Clinical Lipidology, 2014, 8, 279-286.	1.5	13
72	Hemostatic profile in healthy premature neonates; Does birth weight affect the coagulation profile?. Journal of Clinical Neonatology, 2014, 3, 89.	0.2	3

#	Article	IF	CITATIONS
73	CA 19-9 is Associated with Poor Glycemic Control in Diabetic Patients: Role of Insulin Resistance. Clinical Laboratory, 2014, 60, 441-7.	0.5	18
74	Inter-observer reproducibility before and after web-based education in the Gleason grading of the prostate adenocarcinoma among the Iranian pathologists. Acta Medica Iranica, 2014, 52, 370-4.	0.8	4
75	Serum osteoprotegerin in relation to metabolic status, severity, and estimated risk of subsequent coronary heart disease. Archives of Iranian Medicine, 2014, 17, 596-601.	0.6	0
76	Respiratory tract rather than cutaneous atopic allergy inversely associate with multiple sclerosis: A case–control study. Clinical Neurology and Neurosurgery, 2013, 115, 2099-2102.	1.4	6
77	Cardiac malformations in fetuses of gestational and pre gestational diabetic mothers. Iranian Journal of Pediatrics, 2013, 23, 664-8.	0.3	13
78	Inter/intra-observer reproducibility of Gleason scoring in prostate adenocarcinoma in Iranian pathologists. Urology Journal, 2012, 9, 486-90.	0.4	13